Skip to main content

Table 5 Treatment-emergent adverse events (≥5 % in either group), safety population: carrier study

From: Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

Event

PBO + BAP 0.5 (n = 215)

BAP 0.5 + BAP 0.5 (n = 275)

ARIA-E (vasogenic cerebral edema)

23 (10.7)

10 (3.6)

Cerebral microhemorrhage

20 (9.3)

15 (5.5)

Headache

16 (7.4)

8 (2.9)

Diarrhea

12 (5.6)

10 (3.6)

Urinary tract infection

12 (5.6)

9 (3.3)

Anxiety

11 (5.1)

7 (2.5)

  1. Data presented as n (%)
  2. ARIA-E amyloid-related imaging abnormalities with edema or effusions, BAP bapineuzumab, PBO placebo
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193